Catalyst Dossier · compiled by CeliA 🧫

Laboratorios Farmaceuticos Rovi, S.A./ADR (LRVIY)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-31 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

The catalyst path

2026-12-31 (est.)Phase 3 · Etoricoxib + Betamethasone fixed doseimp 9/10

Pipeline

Asset	Phase	Indication
Chlorthalidone 25 mg + amiloride hydrochloride 5 mg	Phase 3	Arterial Hypertension
Depigoid Parietaria judaica 1000DPP/ml	Phase 3	Allergic Rhinoconjunctivitis
Glucosamine and chondroitin sulfate combination (Eurofarma)	Phase 3	Osteoarthritis of Knee
Minoxidil Topical Foam	Phase 3	Alopecia
Study group - quadrivalent recombinant hemagglutinin influenza vaccine	Phase 3	Influenza, Human
Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control	Phase 2	Allergy to Grass Pollen (Dactylis Glomerata)
DP/MG/14-1	Phase 2	Rhinitis
Losartan/Chlorthalidone in fixed dose	Phase 3	Essential Arterial Hypertension
1 (Dose Response Skin Prick Tests)	Phase 2	Cat Allergy (Disorder)
Etoricoxib + Tizanidine fixed dose	Phase 3	Acute Low-back Pain
Levetiracetam	Phase 3	Epilepsy
Grass pollen allergenic extract (L. perenne-C. dactylon )	Phase 2	Allergic Rhinoconjunctivitis
Candicort®	Phase 3	Tinea
Cupressus arizonica	Phase 2	Allergy to Tree Pollen
Glucosamine sulphate and chondroitin sulphate association	Phase 3	Osteoarthritis of the Knee
Group 1	Phase 3	Nasal Congestion and Inflammations
A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)	Phase 3	Type 2 Diabetes
Etoricoxib 90 mg / Tramadol 50 mg	Phase 3	Acute Low Back Pain
Four different concentrations of Poa pratensis allergen extract, positive control and negative control	Phase 2	Allergy to Grass Pollen
Sodium picosulphate, light magnesium oxide and anhydride citric acid.	Phase 3	Subjects Undergoing a Complete Exploratory Diagnostic Colonoscopy for the First Time.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for LRVIY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.